Description

DIOVAAL 80 MG

Indications

DIOVAAL 80 MG is primarily indicated for the management of hypertension and the treatment of heart failure. It is also used in the prevention of cardiovascular events in patients with a history of myocardial infarction or stroke. This medication is suitable for adult patients and may be prescribed as part of a comprehensive treatment plan that includes lifestyle modifications.

Mechanism of Action

DIOVAAL 80 MG contains the active ingredient Valsartan, which is an angiotensin II receptor blocker (ARB). By selectively blocking the binding of angiotensin II to its receptors, Valsartan inhibits the vasoconstrictive effects of this hormone, leading to vasodilation and a subsequent decrease in blood pressure. This action also reduces the secretion of aldosterone, which in turn decreases sodium and water retention, further contributing to the reduction of blood pressure and alleviation of heart failure symptoms.

Pharmacological Properties

DIOVAAL 80 MG exhibits a rapid onset of action, typically within 2 hours after oral administration, with peak plasma concentrations achieved within 4 to 6 hours. The half-life of Valsartan is approximately 9 hours, allowing for once-daily dosing in most cases. The drug is primarily metabolized by the liver and excreted mainly through the feces. Its pharmacokinetics are not significantly affected by food intake, making it convenient for patients to take at any time of the day.

Contraindications

DIOVAAL 80 MG is contraindicated in patients with a known hypersensitivity to Valsartan or any of the excipients in the formulation. It should not be used during pregnancy, particularly in the second and third trimesters, due to the risk of fetal harm. Additionally, this medication is contraindicated in patients with severe hepatic impairment, biliary obstruction, or renal artery stenosis.

Side Effects

Common side effects associated with DIOVAAL 80 MG include dizziness, fatigue, headache, and gastrointestinal disturbances such as nausea and diarrhea. Serious but less common adverse effects may include hypotension, renal impairment, hyperkalemia, and angioedema. Patients should be monitored regularly for these potential side effects, especially during the initiation of therapy or when increasing the dose.

Dosage and Administration

The recommended starting dose of DIOVAAL 80 MG for hypertension is 80 mg once daily. In patients requiring additional blood pressure reduction, the dose may be increased to 160 mg once daily. For heart failure, the initial dose is typically 40 mg once daily, titrated to a target dose of 160 mg once daily based on clinical response and tolerability. It is essential to adhere to the prescribed dosage and consult a healthcare provider before making any adjustments.

Interactions

DIOVAAL 80 MG may interact with other medications, potentially altering its effectiveness or increasing the risk of adverse effects. Notable interactions include non-steroidal anti-inflammatory drugs (NSAIDs), which may reduce the antihypertensive effect of Valsartan. Additionally, potassium-sparing diuretics or potassium supplements should be used cautiously, as they may lead to hyperkalemia. It is crucial for patients to inform their healthcare provider of all medications they are taking to avoid potential drug interactions.

Precautions

Before initiating treatment with DIOVAAL 80 MG, healthcare providers should assess patients for renal function, electrolyte levels, and any history of cardiovascular or renal disease. Special caution is warranted in patients with a history of angioedema, as there is a risk of recurrence. During treatment, regular monitoring of blood pressure, renal function, and potassium levels is recommended, particularly in elderly patients or those with pre-existing conditions.

Clinical Studies

Clinical studies have demonstrated the efficacy of DIOVAAL 80 MG in reducing blood pressure and improving outcomes in patients with heart failure. In a randomized controlled trial, patients treated with Valsartan showed a significant reduction in systolic and diastolic blood pressure compared to placebo. Additionally, studies have indicated that Valsartan can reduce the risk of cardiovascular events in high-risk patients, supporting its role in secondary prevention following myocardial infarction or stroke.

Conclusion

DIOVAAL 80 MG is a valuable therapeutic option for the management of hypertension and heart failure. Its mechanism of action as an angiotensin II receptor blocker provides effective blood pressure control and improved cardiovascular outcomes. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should engage in open communication with their healthcare providers to optimize their treatment and ensure the best possible health outcomes.